Chromosome instability and tumor lethality suppression in carcinogenesis

Journal of Cellular Biochemistry

Volumn 105, Issue 6, 2008, Pages 1327-1341

  Shen, Changxian ^a   Zhou, Yonggang ^b   Zhan, Jun ^a   Reske, Sven N ^c   Buck, Andreas K ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chromosome instability (CIN); High copy suppression; Synthetic survival; Tumor lethality suppression; Tumor lethality suppression addiction

Indexed keywords

CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; DNA DAMAGE; GENE INTERACTION; GENE LOSS; GENE MUTATION; HUMAN; MITOSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DNA DAMAGE; GENES, LETHAL; GENES, TUMOR SUPPRESSOR; HUMANS; MITOSIS; MUTATION; NEOPLASMS;

MUS MUSCULUS;

EID: 57349158759     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21937     Document Type: Review

References (165)

1. Adam J, Deans B, Thacker J. 2007. A role for Xrcc2 in the early stages of mouse development. DNA Repair (Amst) 6:224-234.
2. Aguilera A, Gomez-Gonzalez B. 2008. Genome instability: A mechanistic view of its causes and consequences. Nat Rev Genet 9:204-217.
3. Ajima J, Umezu K, Maki H. 2002. Elevated incidence of loss of heterozygosity (LOH) in an sgs1 mutant of Saccharomyces cerevisiae: Roles of yeast RecQ helicase in suppression of aneuploidy, interchromosomal rearrangement, and the simultaneous incidence of both events during mitotic growth. Mutat Res 504:157-172.
4. Angell RR, Templeton AA, Aitken RJ. 1986. Chromosome studies in human in vitro fertilization. Hum Genet 72:333-339.
5. Astrinidis A, Senapedis W, Coleman TR, Henske EP. 2003. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J Biol Chem 278:51372-51379.
6. Au WC, Crisp MJ, DeLuca SZ, Rando OJ, Basrai MA. 2008. Altered dosage and mislocalization of histone H3 and Cse4p lead to chromosome loss in Saccharomyces cerevisiae. Genetics 179:263-275.
7. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. 1998. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol 8:1395-1398.
8. Bartek J, Lukas J. 2007. DNA damage checkpoints: From initiation to recovery or adaptation. Curr Opin Cell Biol 19:238-245.
9. Bartek J, Lukas C, Lukas J. 2004. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5:792-804.
10. Bielas JH, Loeb LA. 2005. Mutator phenotype in cancer: Timing and perspectives. Environ Mol Mutagen 45:206-213.
11. Boone C, Bussey H, Andrews BJ. 2007. Exploring genetic interactions and networks with yeast. Nat Rev Genet 8:437-449.
12. Bosl WJ, Li R. 2005. Mitotic-exit control as an evolved complex system. Cell 121:325-333.
13. Boveri I. 1902. Ueber mehrpolige mitosen als mittel zur analyse des zellkerns. Verhandlungen der physikalisch-medizinischen geselllschaft zu Wuezburg. Neu Fogle 35:67-90.
14. Branzei D, Foiani M. 2008. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9:297-308.
15. Brown EJ, Baltimore D. 2000. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 14:397-402.
16. Burgess MR, Sawyers CL. 2006. Treating imatinib-resistant leukemia: The next generation targeted therapies. ScientificWorldJournal 6:918-930.
17. Burke DJ, Stukenberg PT. 2008. Linking kinetochore-microtubule binding to the spindle checkpoint. Dev Cell 14:474-479.
18. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. 1999. Genetic instability and darwinian selection in tumours. Trends Cell Biol 9:M57-M60.
19. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
20. Cao L, Kim S, Xiao C, Wang RH, Coumoul X, Wang X, Li WM, Xu XL, De Soto JA, Takai H, Mai S, Elledge SJ, Motoyama N, Deng CX. 2006. ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J 25:2167-2177.
21. Carrell DT. 2008. The clinical implementation of sperm chromosome aneuploidy testing: Pitfalls and promises. J Androl 29:124-133.
22. Cheeseman IM, Desai A. 2008. Molecular architecture of the kinetochore-microtubule interface. Nat Rev Mol Cell Biol 9:33-46.
23. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-730.
24. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW II, Cordon-Cardo C, Yancopoulos GD, DePinho RA. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-472.
25. Chow LM, Baker SJ. 2006. PTEN function in normal and neoplastic growth. Cancer Lett 241:184-196.
26. Clarke A, Orr-Weaver TL. 2006. Sister chromatid cohesion at the centromere: Confrontation between kinases and phosphatases? Dev Cell 10:544-547.
27. Collins I, Workman P. 2006. New approaches to molecular cancer therapeutics. Nat Chem Biol 2:689-700.
28. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VL, Ashworth A. 1997. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 17:423-430.
29. Costa RM, Chigancas V, Galhardo Rda S, Carvalho H, Menck CF. 2003. The eukaryotic nucleotide excision repair pathway. Biochimie 85:1083-1099.
30. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA. 2001. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7:235-239.
31. de Gramont A, Cohen-Fix O. 2005. The many phases of anaphase. Trends Biochem Sci 30:559-568.
32. de Klein A, Muijtjens M, van Os R, Verhoeven Y, Smit B, Carr AM, Lehmann AR, Hoeijmakers JH. 2000. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 10:479-482.
33. de Oca Luna, RM, Tabor AD, Eberspaecher H, Hulboy DL, Worth LL, Colman MS, Finlay CA, Lozano G. 1996. The organization and expression of the mdm2 gene. Genomics 33:352-357.
34. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ. 1994. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA 91:5124-5128.
35. Desany BA, Alcasabas AA, Bachant JB, Elledge SJ. 1998. Recovery from DNA replicational stress is the essential function of the S-phase checkpoint pathway. Genes Dev 12:2956-2970.
36. Dorer DR, Cadden MA, Gordesky-Gold B, Harries G, Christensen AC. 1993. Suppression of a lethal trisomic phenotype in Drosophila melanogaster by increased dosage of an unlinked locus. Genetics 134:243-249.
37. Druker BJ. 2004. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91:1-30.
38. Duesberg P, Stindl R, Hehlmann R. 2000. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 97:14295-14300.
39. Duvel K, Broach JR. 2004. The role of phosphatases in TOR signaling in yeast. Curr Top Microbiol Immunol 279:19-38.
40. Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606-619.
41. Fidler IJ. 2003. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458.
42. Forsdyke DR. 1995. Fine tuning of intracellular protein concentrations, a collective protein function involved in aneuploid lethality, sex-determination and speciation? J Theor Biol 172:335-345.
43. Frank KM, Sekiguchi JM, Seidl KJ, Swat W, Rathbun GA, Cheng HL, Davidson L, Kangaloo L, Alt FW. 1998. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 396:173-177.
44. Friedberg EC. 2001. How nucleotide excision repair protects against cancer. Nat Rev Cancer 1:22-33.
45. Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM, Chaudhuri J, Horner J, DePinho RA, Alt FW. 2000. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404:897-900.
46. Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. 2008. Defining 'chromosomal instability'. Trends Genet 24:64-69.
47. Generoso WM, Katoh M, Cain KT, Hughes LA, Foxworth LB, Mitchell TJ, Bishop JB. 1989. Chromosome malsegregation and embryonic lethality induced by treatment of normally ovulated mouse oocytes with nocodazole. Mutat Res 210:313-322.
48. Giacinti C, Giordano A. 2006. RB and cell cycle progression. Oncogene 25:5220-5227.
49. Giaretti W, Pujic N, Rapallo A, Nigro S, Di Vinci A, Geido E, Risio M. 1995. K-ras-2 G-C and G-T transversions correlate with DNA aneuploidy in colorectal adenomas. Gastroenterology 108:1040-1047.
50. Graat HC, Carette JE, Schagen FH, Vassilev LT, Gerritsen WR, Kaspers GJ, Wuisman PI, van Beusechem VW. 2007. Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther 6:1552-1561.
51. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12:9-22.
52. Hahn WC, Weinberg RA. 2002. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341.
53. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
54. Harper JW, Elledge SJ. 2007. The DNA damage response: Ten years after. Mol Cell 28:739-745.
55. Harris SL, Levine AJ. 2005. The p53 pathway: Positive and negative feedback loops. Oncogene 24:2899-2908.
56. Harrison JC, Haber JE. 2006. Surviving the breakup: The DNA damage checkpoint. Annu Rev Genet 40:209-235.
57. Hartman JLt, Garvik B, Hartwell L. 2001. Principles for the buffering of genetic variation. Science 291:1001-1004.
58. Hartwell LH, Kastan MB. 1994. Cell cycle control and cancer. Science 266:1821-1828.
59. Harwood FC, Shu L, Houghton PJ. 2008. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J Biol Chem 283:2575-2585.
60. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004.
61. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. 2004. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430:797-802.
62. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483.
63. Hu F, Alcasabas AA, Elledge SJ. 2001a. Asf1 links Rad53 to control of chromatin assembly. Genes Dev 15:1061-1066.
64. Hu F, Wang Y, Liu D, Li Y, Qin J, Elledge SJ. 2001b. Regulation of the Bub2/ Bfa1 GAP complex by Cdc5 and cell cycle checkpoints. Cell 107:655-665.
65. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, Evan GI. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278:1305-1309.
66. Hulit J, Di Vizio D, Pestell RG. 2001. Inducible transgenics. New lessons on events governing the induction and commitment in mammary tumorigenesis. Breast Cancer Res 3:209-212.
67. Jacinto E, Hall MN. 2003. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117-126.
68. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208.
69. Kaelin WG, Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698.
70. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.
71. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-170.
72. Kitajima TS, Sakuno T, Ishiguro K, Iemura S, Natsume T, Kawashima SA, Watanabe Y. 2006. Shugoshin collaborates with protein phosphatase 2A to protect cohesin. Nature 441:46-52.
73. Klein HL. 2001. Spontaneous chromosome loss in Saccharomyces cerevisiae is suppressed by DNA damage checkpoint functions. Genetics 159:1501-1509.
74. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162.
75. Knudson AG, Jr. 1984. Genetic predisposition to cancer. Cancer Detect Prev 7:1-8.
76. Kops GJ, Foltz DR, Cleveland DW. 2004. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci USA 101:8699-8704.
77. Kops GJ, Weaver BA, Cleveland DW. 2005. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5:773-785.
78. Kroll ES, Hyland KM, Hieter P, Li JJ. 1996. Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 143:95-102.
79. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396:643-649.
80. Letai AG. 2008. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8:121-132.
81. Lew DJ, Burke DJ. 2003. The spindle assembly and spindle position checkpoints. Annu Rev Genet 37:251-282.
82. Li W, Zhu T, Guan KL. 2004. Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. J Biol Chem 279:37398-37406.
83. Liang F, Wang Y. 2007. DNA damage checkpoints inhibit mitotic exit by two different mechanisms. Mol Cell Biol 27:5067-5078.
84. Loeb LA. 1991. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075-3079.
85. Loeb LA, Bielas JH, Beckman RA. 2008. Cancers exhibit a mutator phenotype: Clinical implications. Cancer Res 68:3551-3557; discussion 3557.
86. Lowe SW, Cepero E, Evan G. 2004. Intrinsic tumour suppression. Nature 432:307-315.
87. Lu Y, Wang H, Mills GB. 2003. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 7:205-228.
88. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. 1997. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11:1226-1241.
89. Luo J, Manning BD, Cantley LC. 2003. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 4:257-262.
90. Manning BD, Cantley LC. 2007. AKT/PKB signaling: Navigating downstream. Cell 129:1261-1274.
91. Marx J. 2002. Debate surges over the origins of genomic defects in cancer. Science 297:544-546.
92. McAllister KA, Bennett LM, Houle CD, Ward T, Malphurs J, Collins NK, Cachafeiro C, Haseman J, Goulding EH, Bunch D, Eddy EM, Davis BJ, Wiseman RW. 2002. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res 62:990-994.
93. Measday V, Hieter P. 2002. Synthetic dosage lethality. Methods Enzymol 350:316-326.
94. Memisoglu A, Samson L. 2000. Base excision repair in yeast and mammals. Mutat Res 451:39-51.
95. Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB. 2008. The molecular basis of cancer. Philadelphia: Elsevier Inc.; p XV.
96. Musacchio A, Salmon ED. 2007. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8:379-393.
97. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. 2006. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280.
98. Nasmyth K. 2002. Segregating sister genomes: The molecular biology of chromosome separation. Science 297:559-565.
99. Nasmyth K, Haering CH. 2005. The structure and function of SMC and kleisin complexes. Annu Rev Biochem 74:595-648.
100. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. 2002. Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36:617-656.
101. Osborn AJ, Elledge SJ, Zou L. 2002. Checking on the fork: The DNA-replication stress-response pathway. Trends Cell Biol 12:509-516.
102. Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. 2007. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther 14:543-549.
103. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29:92-95.
104. Queralt E, Lehane C, Novak B, Uhlmann F. 2006. Downregulation of PP2A(Cdc55) phosphatase by separase initiates mitotic exit in budding yeast. Cell 125:719-732.
105. Rajagopalan H, Lengauer C. 2004. Aneuploidy and cancer. Nature 432:338-341.
106. Ramey CJ, Howar S, Adkins M, Linger J, Spicer J, Tyler JK. 2004. Activation of the DNA damage checkpoint in yeast lacking the histone chaperone anti-silencing function 1. Mol Cell Biol 24:10313-10327.
107. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
108. Riedel CG, Katis VL, Katou Y, Mori S, Itoh T, Helmhart W, Galova M, Petronczki M, Gregan J, Cetin B, Mudrak I, Ogris E, Mechtler K, Pelletier L, Buchholz F, Shirahige K, Nasmyth K. 2006. Protein phosphatase 2A protects centromeric sister chromatid cohesion during meiosis I. Nature 441:53-61.
109. Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412
110. Rodier F, Campisi J, Bhaumik D. 2007. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res 35:7475-7484.
111. Rossi DJ, Jamieson CH, Weissman IL. 2008. Stems cells and the pathways to aging and cancer. Cell 132:681-696.
112. Rouse J, Jackson SP. 2002. Interfaces between the detection, signaling, and repair of DNA damage. Science 297:547-551.
113. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA. 2000. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19:3948-3954.
114. Sabatini DM. 2006. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6:729-734.
115. Sallmyr A, Fan J, Rassool FV. 2008. Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 270:1-9.
116. Salmena L, Carracedo A, Pandolfi PP. 2008. Tenets of PTEN tumor suppression. Cell 133:403-414.
117. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. 2004. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39-85.
118. Savona M, Talpaz M. 2008. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8:341-350.
119. Sawyers C. 2004. Targeted cancer therapy. Nature 432:294-297.
120. Sawyers CL. 2008. The cancer biomarker problem. Nature 452:548-552.
121. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308.
122. Sharma SV, Settleman J. 2007. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 21:3214-3231.
123. Sharom JR, Bellows DS, Tyers M. 2004. From large networks to small molecules. Curr Opin Chem Biol 8:81-90.
124. Shaw RJ, Cantley LC. 2006. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430.
125. Shen C, Lancaster CS, Shi B, Guo H, Thimmaiah P, Bjornsti MA. 2007a. TOR signaling is a determinant of cell survival in response to DNA damage. Mol Cell Biol 27:7007-7017.
126. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. 2007b. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:157-170.
127. Sherr CJ. 2000. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res 60:3689-3695.
128. Sherr CJ. 2004. Principles of tumor suppression. Cell 116:235-246.
129. Shiloh Y. 2003. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 3:155-168.
130. Siveke JT, Schmid RM. 2005. Chromosomal instability in mouse metastatic pancreatic cancer - It's Kras and Tp53 after all. Cancer Cell 7:405-407.
131. Sonnenschein C, Soto AM. 2008. Theories of carcinogenesis: An emerging perspective. Semin Cancer Biol 18:372-377.
132. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW, Benezra R. 2007. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11:9-23.
133. Stegmeier F, Amon A. 2004. Closing mitosis: The functions of the Cdc14 phosphatase and its regulation. Annu Rev Genet 38:203-232.
134. Stingl J, Caldas C. 2007. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7:791-799.
135. Su TT. 2006. Cellular responses to DNA damage: One signal, multiple choices. Annu Rev Genet 40:187-208.
136. Sullivan M, Morgan DO. 2007. Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 8:894-903.
137. Sung P, Klein H. 2006. Mechanism of homologous recombination: Mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol 7:739-750.
138. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711.
139. Tang Z, Shu H, Qi W, Mahmood NA, Mumby MC, Yu H. 2006. PP2A is required for centromeric localization of Sgo1 and proper chromosome segregation. Dev Cell 10:575-585.
140. Ternovoi VV, Curiel DT, Smith BF, Siegal GP. 2006. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab Invest 86:748-766.
141. Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Page N, Robinson M, Raghibizadeh S, Hogue CW, Bussey H, Andrews B, Tyers M, Boone C. 2001. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 294:2364-2368.
142. Tong AH, Lesage G, Bader GD, Ding H, Xu H, Xin X, Young J, Berriz GF, Brost RL, Chang M, Chen Y, Cheng X, Chua G, Friesen H, Goldberg DS, Haynes J, Humphries C, He G, Hussein S, Ke L, Krogan N, Li Z, Levinson JN, Lu H, Menard P, Munyana C, Parsons AB, Ryan O, Tonikian R, Roberts T, Sdicu AM, Shapiro J, Sheikh B, Suter B, Wong SL, Zhang LV, Zhu H, Burd CG, Munro S, Sander C, Rine J, Greenblatt J, Peter M, Bretscher A, Bell G, Roth FP, Brown GW, Andrews B, Bussey H, Boone C. 2004. Global mapping of the yeast genetic interaction network. Science 303:808-813.
143. Torres EM, Williams BR, Amon A. 2008. Aneuploidy: Cells losing their balance. Genetics 179:737-746.
144. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. 2005. Erlotinib in lung cancer - Molecular and clinical predictors of outcome. N Engl J Med 353:133-144.
145. van Deursen JM. 2007. Rb loss causes cancer by driving mitosis mad. Cancer Cell 11:1-3.
146. van Gent DC, van der Burg M. 2007. Non-homologous end-joining, a sticky affair. Oncogene 26:7731-7740.
147. Varmus H. 2006. The new era in cancer research. Science 312:1162-1165.
148. Vogelstein B, Kinzler KW. 1993. The multistep nature of cancer. Trends Genet 9:138-141.
149. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10:789-799.
150. Wang W, El-Deiry WS. 2008. Restoration of p53 to limit tumor growth. Curr Opin Oncol 20:90-96.
151. Wang Y, Hu F, Elledge SJ. 2000. The Bfa1/Bub2 GAP complex comprises a universal checkpoint required to prevent mitotic exit. Curr Biol 10:1379-1382.
152. Weaver BA, Cleveland DW. 2005. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8:7-12.
153. Weinberg RA. 1984. Oncogenes and the molecular basis of cancer. Harvey Lect 80:129-136.
154. Weinberg RA. 1991. Tumor suppressor genes. Science 254:1138-1146.
155. Weinberg RA. 2007. The biology of cancer. New York: Garland Science.
156. Weinstein IB. 2002. Cancer: Addiction to oncogenes - The Achilles heal of cancer. Science 297:63-64.
157. Weinstein IB, Joe A. 2008. Oncogene addiction. Cancer Res 68:3077-3080; discussion 3080.
158. Weterings E, Chen DJ. 2008. The endless tale of non-homologous end-joining. Cell Res 18:114-124.
159. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
160. Wullschleger S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. Cell 124:471-484.
161. Yu HG, Koshland D. 2007. The Aurora kinase Ipl1 maintains the centromeric localization of PP2A to protect cohesin during meiosis. J Cell Biol 176:911-918.
162. Zhang J, Gray J, Wu L, Leone G, Rowan S, Cepko CL, Zhu X, Craft CM, Dyer MA. 2004. Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat Genet 36:351-360.
163. Zhang C, Roberts TM, Yang J, Desai R, Brown GW. 2006. Suppression of genomic instability by SLX5 and SLX8 in Saccharomyces cerevisiae. DNA Repair (Amst) 5:336-346.
164. Zhao X, Muller EG, Rothstein R. 1998. A suppressor of two essential checkpoint genes identifies a novel protein that negatively affects dNTP pools. Mol Cell 2:329-340.
165. Zhou BB, Elledge SJ. 2000. The DNA damage response: Putting checkpoints in perspective. Nature 408:433-439.